Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282023892> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4282023892 endingPage "e24090" @default.
- W4282023892 startingPage "e24090" @default.
- W4282023892 abstract "e24090 Background: Patients receiving Highly Emetogenic chemotherapy (HEC) are > 90% risk of nausea-vomiting due to the drug's emetogenic potential and patient-related factors such as young age, female gender, low/no alcohol, H/O morning sickness and use of alternative medications. The current study was designed to assess the effectiveness of NEPA in patients receiving HEC in a real-world setting in India. Methods: An open-label, single-arm, prospective study among chemonaive patients was conducted across six centers from April 2019 to December 2021 after approval from each institutional ethics committee (CTRI/2020/02/023586). Complete response and treatment-emergent adverse events were the primary endpoints. Secondary endpoints included completion protection, complete control and severity of nausea. Results: HEC regimens were prescribed in 289 of the 360 patients enrolled in the study. Most common HEC regimen was Anthracycline-Cyclophosphamide (44.2%) followed by Paclitaxel-Carboplatin (17.9%). Average age of study population was 52.8±9.8 yrs. with male: female ratio of 1:2.1. Hypertension (17.6%) and diabetes (12.4%) were common comorbidities. Complete response in acute, delayed and overall phases were 94.4%, 94.8%, and 92.7% respectively. In overall phase, complete protection and complete control was 86.8% and 77.5% respectively. Mild, moderate and severe nausea were reported in 11.7%, 7.6%, and 2.4%, patients respectively. Adverse events were seen in 10(3.4%) patients, with leg pain being the most common 3(0.8%). One serious adverse event, unrelated to the study drug was reported. Conclusions: NEPA was effective and well tolerated in patients on a HEC regimen in the acute, delayed and overall phases with a completed response rate of > 90%. Clinical trial information: CTRI/2020/02/023586. [Table: see text]" @default.
- W4282023892 created "2022-06-13" @default.
- W4282023892 creator A5019138933 @default.
- W4282023892 creator A5026538013 @default.
- W4282023892 creator A5036393500 @default.
- W4282023892 creator A5044799442 @default.
- W4282023892 creator A5048143305 @default.
- W4282023892 creator A5065710121 @default.
- W4282023892 creator A5075153702 @default.
- W4282023892 creator A5075467464 @default.
- W4282023892 creator A5079746705 @default.
- W4282023892 creator A5080910293 @default.
- W4282023892 date "2022-06-01" @default.
- W4282023892 modified "2023-09-28" @default.
- W4282023892 title "Effectiveness of NEPA, an oral fixed-dose combination of NEtupitant and PAlonosetron in the prevention of chemotherapy-induced nausea-vomiting in patient receiving highly emetogenic chemotherapy regimens." @default.
- W4282023892 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e24090" @default.
- W4282023892 hasPublicationYear "2022" @default.
- W4282023892 type Work @default.
- W4282023892 citedByCount "0" @default.
- W4282023892 crossrefType "journal-article" @default.
- W4282023892 hasAuthorship W4282023892A5019138933 @default.
- W4282023892 hasAuthorship W4282023892A5026538013 @default.
- W4282023892 hasAuthorship W4282023892A5036393500 @default.
- W4282023892 hasAuthorship W4282023892A5044799442 @default.
- W4282023892 hasAuthorship W4282023892A5048143305 @default.
- W4282023892 hasAuthorship W4282023892A5065710121 @default.
- W4282023892 hasAuthorship W4282023892A5075153702 @default.
- W4282023892 hasAuthorship W4282023892A5075467464 @default.
- W4282023892 hasAuthorship W4282023892A5079746705 @default.
- W4282023892 hasAuthorship W4282023892A5080910293 @default.
- W4282023892 hasConcept C126322002 @default.
- W4282023892 hasConcept C197934379 @default.
- W4282023892 hasConcept C203092338 @default.
- W4282023892 hasConcept C2776694085 @default.
- W4282023892 hasConcept C2776712918 @default.
- W4282023892 hasConcept C2778336483 @default.
- W4282023892 hasConcept C2779924295 @default.
- W4282023892 hasConcept C2780574406 @default.
- W4282023892 hasConcept C2780580376 @default.
- W4282023892 hasConcept C2780852908 @default.
- W4282023892 hasConcept C2780884295 @default.
- W4282023892 hasConcept C2781413609 @default.
- W4282023892 hasConcept C2908647359 @default.
- W4282023892 hasConcept C535046627 @default.
- W4282023892 hasConcept C71924100 @default.
- W4282023892 hasConcept C99454951 @default.
- W4282023892 hasConceptScore W4282023892C126322002 @default.
- W4282023892 hasConceptScore W4282023892C197934379 @default.
- W4282023892 hasConceptScore W4282023892C203092338 @default.
- W4282023892 hasConceptScore W4282023892C2776694085 @default.
- W4282023892 hasConceptScore W4282023892C2776712918 @default.
- W4282023892 hasConceptScore W4282023892C2778336483 @default.
- W4282023892 hasConceptScore W4282023892C2779924295 @default.
- W4282023892 hasConceptScore W4282023892C2780574406 @default.
- W4282023892 hasConceptScore W4282023892C2780580376 @default.
- W4282023892 hasConceptScore W4282023892C2780852908 @default.
- W4282023892 hasConceptScore W4282023892C2780884295 @default.
- W4282023892 hasConceptScore W4282023892C2781413609 @default.
- W4282023892 hasConceptScore W4282023892C2908647359 @default.
- W4282023892 hasConceptScore W4282023892C535046627 @default.
- W4282023892 hasConceptScore W4282023892C71924100 @default.
- W4282023892 hasConceptScore W4282023892C99454951 @default.
- W4282023892 hasIssue "16_suppl" @default.
- W4282023892 hasLocation W42820238921 @default.
- W4282023892 hasOpenAccess W4282023892 @default.
- W4282023892 hasPrimaryLocation W42820238921 @default.
- W4282023892 hasRelatedWork W1480067006 @default.
- W4282023892 hasRelatedWork W2018428965 @default.
- W4282023892 hasRelatedWork W2032692004 @default.
- W4282023892 hasRelatedWork W2076161482 @default.
- W4282023892 hasRelatedWork W2108765055 @default.
- W4282023892 hasRelatedWork W2466185265 @default.
- W4282023892 hasRelatedWork W2789861325 @default.
- W4282023892 hasRelatedWork W2890268286 @default.
- W4282023892 hasRelatedWork W3006775094 @default.
- W4282023892 hasRelatedWork W3019368182 @default.
- W4282023892 hasVolume "40" @default.
- W4282023892 isParatext "false" @default.
- W4282023892 isRetracted "false" @default.
- W4282023892 workType "article" @default.